Scarica l'app Stockscreener
97.50
1.68%
1.61
Precedente Chiudi:
$95.89
Aprire:
$96.67
Volume 24 ore:
441.55K
Relative Volume:
0.49
Capitalizzazione di mercato:
$3.80B
Reddito:
$117.67M
Utile/perdita netta:
$-1.88B
Rapporto P/E:
-1.6106
EPS:
-60.5369
Flusso di cassa netto:
$-621.36M
1 W Prestazione:
-2.57%
1M Prestazione:
-4.38%
6M Prestazione:
+186.93%
1 anno Prestazione:
+85.43%
Intervallo 1D:
$94.75
$99.85
Intervallo di 1 settimana:
$92.50
$106.00
Portata 52W:
$20.44
$118.84
Grail Inc Stock (GRAL) Company Profile
Nome
Grail Inc
Settore
Industria
Telefono
(833) 694-2553
Indirizzo
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
97.50 | 3.74B | 117.67M | -1.88B | -621.36M | -60.54 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-11-12 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-04-21 | Iniziato | Canaccord Genuity | Buy |
| 2024-11-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-10-17 | Iniziato | Guggenheim | Neutral |
Mostra tutto
Grail Inc Borsa (GRAL) Ultime notizie
Commit To Purchase Grail At $50, Earn 22% Using Options - Nasdaq
GRAIL (GRAL) Projected to Post Earnings on Thursday - MarketBeat
Why analysts recommend GRAIL Inc. (NL0) stockJuly 2025 Update & Capital Protection Trade Alerts - mfd.ru
GRAIL Inc (GRAL) Shares Up 5.15% on Feb 10 - GuruFocus
GRAIL, Inc. (GRAL) Stock Analysis: Healthcare Innovator With Potential 14.54% Upside - DirectorsTalk Interviews
GRAIL submits FDA PMA for Galleri multi-cancer early detection test - MSN
Samsung and GRAIL Announce Strategic Collaboration To Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia - Samsung Global Newsroom
Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time. - Barron's
Moloney Securities Asset Management LLC Has $959,000 Stock Holdings in GRAIL, Inc. $GRAL - MarketBeat
A $700 blood test promises to detect 50 different kinds of cancer. The results come with major caveats. - Business Insider
GRAIL, Inc. $GRAL Shares Purchased by Allianz Asset Management GmbH - MarketBeat
What GRAIL (GRAL)'s FDA PMA Submission for Galleri Test Means For Shareholders - Sahm
Is It Too Late To Consider GRAIL (GRAL) After A 186% One Year Surge? - Yahoo Finance
How The GRAIL (GRAL) Story Is Shifting With Galleri And New Valuation Clues - Yahoo Finance
Hims & Hers Launches GRAIL Multi Cancer Screening Test - GuruFocus
Hims Briefly Pops, And Then Dives, After Scoring A Key Deal - Investor's Business Daily
Hims & Hers Shares In The Spotlight After Launching Multi-Cancer Test - Benzinga
Hims & Hers rolls out GRAIL’s multi cancer screening test - Seeking Alpha
Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care - Hims Investor Relations
Hims adds cancer detection test to Labs product - Sherwood News
GRAIL, Inc. (GRAL) Investor Outlook: A Healthcare Innovator With 10.93% Upside Potential - DirectorsTalk Interviews
GRAIL Inc (GRAL) Shares Up 3.77% on Feb 2 - GuruFocus
Grail files for FDA approval of multi-cancer early detection test - MedTech Dive
Y Intercept Hong Kong Ltd Purchases Shares of 14,959 GRAIL, Inc. $GRAL - MarketBeat
GRAIL, Inc.'s (NASDAQ:GRAL) Institutional Investors Lost 13% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
GRAIL (GRAL) Price Target Increased by 46.34% to 91.80 - MSN
GRAIL Submits FDA Premarket Approval Application for Galleri Multi-Cancer Early Detection Blood Test - Patient Care Online
GRAIL Submits FDA PMA for Galleri Multi-Cancer Early Detection Test - sharewise.com
GRAIL (GRAL) Is Down 13.0% After Final PMA Module Filing for Galleri Multi-Cancer Test - Sahm
Trifecta Capital Advisors LLC Purchases 10,250 Shares of GRAIL, Inc. $GRAL - MarketBeat
Grail Submits Premarket Approval Application to FDA for Multi-Cancer Early Detection Test - marketscreener.com
Grail raised to Buy at Guggenheim on potential of Galleri - MSN
Grail submits FDA premarket approval appplication for Galleri - TipRanks
GRAIL's Galleri multi-cancer test takes key step toward FDA approval - stocktitan.net
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test - Prime Publishers, Inc.
Assessing GRAIL (GRAL) Valuation After Analyst Upgrades And Strong Recent Shareholder Returns - simplywall.st
GRAIL Inc (GRAL) Trading Down 7.75% on Jan 28 - GuruFocus
Multi Cancer Early Detection Market Is Going to Boom |• GRAIL • Freenome • Thrive Earlier Detection - openPR.com
Why (GRAL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Beyond The Numbers: 4 Analysts Discuss GRAIL Stock - Benzinga
GRAIL Inc.: Strong Galleri Momentum and Upcoming Regulatory Catalysts Support Buy Rating and $105 Target - TipRanks
Guggenheim Raises GRAIL (GRAL) Price Target to $130 | GRAL Stock News - GuruFocus
Why GRAIL Inc Shares Are Surging Higher Now - TipRanks
Grail price target raised to $130 from $100 at Guggenheim - TipRanks
How Is The Market Feeling About GRAIL Inc? - Benzinga
Canaccord Genuity reiterates Buy rating on GRAIL stock with $105 target - Investing.com
GRAIL Stock (-9.6%) : Guidance Disappoints + Valuation Reset - Trefis
GRAIL (NASDAQ:GRAL) Trading Down 7.7%Here's Why - MarketBeat
Why GRAIL Inc Shares Are Sliding Despite Guidance - TipRanks
No News JSON Data Available - StocksToTrade
GRAIL stock jumps as Galleri outlook and FDA filing timeline come back into focus - TechStock²
Grail Inc Azioni (GRAL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):